| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 30.84% | Piper Sandler | $3.5 → $4.5 | Maintains | Overweight |
| 06/12/2023 | -12.77% | Piper Sandler | → $3 | Initiates Coverage On | → Overweight |
| 05/17/2023 | 38.11% | National Alliance Securities | $5.15 → $4.75 | Maintains | Buy |
| 03/31/2023 | 49.74% | Alliance Global Partners | $5.6 → $5.15 | Maintains | Buy |
| 10/16/2020 | -79.65% | Alliance Global Partners | → $0.7 | Initiates Coverage On | → Buy |
| 03/11/2020 | -41.85% | HC Wainwright & Co. | $5 → $2 | Reiterates | → Buy |
What is the target price for InspireMD (NSPR)?
The latest price target for InspireMD (NASDAQ: NSPR) was reported by Piper Sandler on November 2, 2023. The analyst firm set a price target for $4.50 expecting NSPR to rise to within 12 months (a possible 30.84% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for InspireMD (NSPR)?
The latest analyst rating for InspireMD (NASDAQ: NSPR) was provided by Piper Sandler, and InspireMD maintained their overweight rating.
When is the next analyst rating going to be posted or updated for InspireMD (NSPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InspireMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InspireMD was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating InspireMD (NSPR) correct?
While ratings are subjective and will change, the latest InspireMD (NSPR) rating was a maintained with a price target of $3.50 to $4.50. The current price InspireMD (NSPR) is trading at is $3.44, which is out of the analyst's predicted range.